INGN 241, a new drug that directly virsuachtig tumor to be injected, gives a phase I study in 22 cancer patients 100% result. Article posted June 2005

June 9, 2005: Source: Mol There. January 2005, 11 (1) :160-72.

An injection of a virus-like drug, code-named gives INGN 241 phase I trial in 22 cancer patients 100% result. The abstract is medically difficult to understand for lay people but the approach resembles the approach of the Newcastle virus . In or near the tumor is a virus-like drug injected and this seems the suicide of cancer cells and stiumuleren stimulleert to the immmuunsysteem and gives no side effects because it leaves healthy cells intact. A special development. The address of Inrogen Inc.. The producer of this INGN 241 is under the address of Introgen , only for OPS members Mol There. January 2005, 11 (1) :160-72.

Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma differentiation-associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.

Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K, Coffee K, Ramesh R, Ekmekcioglu S, Grimm EA, of Wart Hood J, Merritt J, S. Chada
Baylor Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75246, USA.

The mda-7 gene (approved gene symbol IL24) is a novel tumor suppressor gene with tumor-apoptotic and immune-activating properties. We completed a Phase I dose-escalation clinical trial, in Which a nonreplicating adenoviral construct expressing the mda-7 transgene (INGN 241, Ad-mda7) was Administered intratumorally to 22 patients with advanced cancer. Excised tumors Were Evaluated for vector-specific DNA and RNA, transgenic MDA-7 expression, and biological effects. Successful gene transfer as assessed by RT-PCR and DNA was demonstrated in 100% of Patients Evaluated. DNA analysis demonstrated a dose-dependent penetration of INGN 241 (up to 4 x 10 (8) copies / mug DNA at the 2 x 10 (12) vp dose). A parallel distribution of vector DNA, vector RNA, MDA-7 protein expression, and apoptosis induction was observed in all tumors, with Decreasing signals with distance away from the injection site. Additional evidence for bioactivity of INGN 241 was illustrated via regulation of the MDA-7 beta-catenin target genes, iNOS, and CD31. Transient increases (up to 20-fold) and serum IL-6, IL-10, and TNF-alpha Were observed. Significantly higher Elevation of IL-6 and TNF-alpha Were Clinically observed in patient who responded to INGN 241. Also Patients showed marked increases of CD3 + CD8 + T cells post-treatment, Suggesting That INGN 241 Increased systemic TH1 cytokine production and mobilized CD8 + T cells. Intratumoral delivery of INGN 241 induced apoptosis in a large volume of tumor and elicited tumor-regulatory and immune-activating Events that are consistent with the preclinical features or MDA-7/IL-24.

Publication Types:
Clinical Trial
Clinical Trial, Phase I

PMID: 15585417 [PubMed - indexed for MEDLINE]